Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5191241 | 0.83 | NOS2 (0.62) | NOS2 | |
| SCHEMBL6328459 | 0.82 | NOS2 (0.47) | NOS2 | |
| SCHEMBL7617066 | 0.79 | NOS2 (0.43) | NOS2 | |
| SCHEMBL7062075 | 0.79 | NOS2 (0.42) | NOS2 | |
| SCHEMBL5191423 | 0.78 | NOS2 (0.59) | NOS2 | |
| SCHEMBL5192827 | 0.77 | NOS2 (0.68) | NOS2 | |
| SCHEMBL6324810 | 0.77 | NOS2 (0.52) | NOS2 | |
| SCHEMBL5193325 | 0.76 | NOS2 (0.66) | NOS2 | |
| SCHEMBL5189790 | 0.76 | NOS2 (0.70) | NOS2 | |
| SCHEMBL5192757 | 0.75 | NOS2 (0.67) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6849739-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6841673-B2 | N-heterocyclic derivatives as nos inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.